Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Basit Öğe Kaydı
dc.authoridÖzkanlı, Gülhan / 0000-0003-3912-7191
dc.contributor.authorKahraman, Seda
dc.contributor.authorHizal, Mutlu
dc.contributor.authorÇakan Demirel, Burçin
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorGümüşay, Özge
dc.contributor.authorOyan Uluç, Başak
dc.contributor.authorBayram, Ertuğrul
dc.contributor.authorÖzkanlı, Gülhan
dc.date.accessioned2025-01-27T20:38:37Z
dc.date.available2025-01-27T20:38:37Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractHighly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials. To contribute to the literature, we investigated the real-world efficacy, factors associated with survival and the rates of adverse events (AEs) of the treatment with palbociclib or ribociclib plus ET in the HR+/HER2- MBC patient cohort over the age of 65 for age subgroups. In this retrospective study, 348 patients were divided into subgroups: 65-69 years old, 70-79 years old and 80 years and older. Median PFS (mPFS) for whole group was 18.3 (95% CI,14.3-22.3) months. There was no significant difference in mPFS between age groups (p = 0.75). The estimated median OS (mOS) was 39.5 (95% CI, 24.9-54.1) months and there was no significant difference between age groups (p = 0.15). There was a meaningfull numerical difference that did not reach statistical significance in patients who received CDK4/6i treatment as the first line for MBC. Grade 3-4 AEs were reported in 42.7% for the entire group, and neutropenia was the most common (37.3%). It can be concluded that combination therapy with palbociclib or ribociclib with an ET partner has similar efficacy and is safe among subgroups of older patients diagnosed with HR+/HER2-MBC.
dc.identifier.doi10.1186/s12885-024-13357-5
dc.identifier.issn1471-2407
dc.identifier.issue1
dc.identifier.pmid39736618
dc.identifier.scopus2-s2.0-85213690636
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s12885-024-13357-5
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23671
dc.identifier.volume24
dc.identifier.wosWOS:001389279700004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBMC
dc.relation.ispartofBmc Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectCDK 4/6 inhibitors
dc.subjectMetastatic breast cancer
dc.subjectGeriatric population
dc.titleActivity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Gulhan Ozkanli_Makale.pdf
Boyut:
1.82 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu